Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

What this study is about

The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.

Who can join (things the study team will check)

✅ You may be able to join if…

• Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)
• No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease
• Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only
• Sarcoma not originating from bone or abdominal or gynecological viscera
• Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)
• WHO performance status 0-2
• American Society of Anaesthesiologist (ASA) score 1-3
• No prior RT for the retroperitoneal liposarcoma
• Prior systemic therapy is allowed
• No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)
• Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment
• Patient deemed able to comply with study requirements according to investigator evaluation
• Signed, IRB-approved written informed consent

🚫 You may not be able to join if…

• Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team
• Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible
• Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease
• Myxoid liposarcoma histology
• Pregnancy

Where this trial is running

• Emory Winship Cancer Institute, Atlanta, Georgia, United States
• OSU James Hospital, Columbus, Ohio, United States
• MD Anderson Cancer Center, Houston, Texas, United States
• Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
• Prince of Wales Hospital, Randwick, New South Wales, Australia
• Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
• UZ Leuven, Leuven, Flemish Brabant, Belgium
• A.C.Camargo Cancer Center - Fundacao Antonio Prudente, Liberdade, São Paulo, Brazil
• The Princess Margaret Cancer Centre, Toronto, Ontario, Canada
• Institut Curie Hospital, Paris, France
• The Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands

Who to contact

Janina Chapman · 61414316490 · janina.chapman@petermac.org

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07377747.